Foam Sclerotherapy Using Polidocanol (Aethoxysklerol) for Preoperative Portal Vein Embolization in 16 Patients

Journal Article · Thu Dec 15 00:00:00 EST 2011 · Cardiovascular and Interventional Radiology

DOI:https://doi.org/10.1007/S00270-010-0079-5· OSTI ID:21608643

Chung, Sang-Hoon; Lee, Myung-su ^[1]; Kim, Kyung Sik; Kim, Soon II ^[2]; Won, Jong Youn ^[3]; Lee, Do Yun; Lee, Kwang-Hun ^[1]

---

1. University of Yonsei, Department of Radiology and Research Institute of Radiologic Science, Severance Hospital, College of Medicine (Korea, Republic of)
2. University of Yonsei, Department of Surgery, Severance Hospital, College of Medicine (Korea, Republic of)
3. University of Yonsei, Department of Radiology, Gangnam Severance Hospital, College of Medicine (Korea, Republic of)

Purpose: To evaluate the clinical safety and effectiveness of foam sclerotherapy using polidocanol for preoperative portal vein embolization (PVE) before hemihepatectomy of the liver. Materials and Methods: From March 2006 to October 2008, foam sclerotherapy using polidocanol was performed in 16 patients (male-to-female ratio of 12:4, age range 48-75 years [mean 62]) for PVE. Patients were diagnosed with Klatskin tumor (n = 13), gallbladder (GB) cancer (n = 2), or hepatocellular carcinoma (HCC) (n = 1). The foam was composed of a 1:2:1 ratio of 3% polidocanol (Aethoxysklerol; Kreussler Pharma, Wiesbaden, Germany), room air, and contrast media (Xenetix 350; Guerbet, Aulnay-Sous-Bois, France). The total amount of polidocanol used (2 to 8 mL [mean 4.6]) varied according to the volume of the target portal vein. We calculated the volume of future liver remnant (FLR) before and after PVE and evaluated complications associated with the use of polidocanol foam sclerotherapy for PVE. Results: Technical success was achieved in all patients. All patients were comfortable throughout the procedure and did not experience pain during sclerotherapy. No periprocedural morbidity or mortality occurred. Patients underwent a liver dynamic computed tomography (CT) scan 2-4 weeks after PVE. FLR increased significantly after PVE using polidocanol foam from 19.3% (range 16-35%) before PVE to 27.8% (range 23-42%) after PVE (p = 0.001). All patients were operable for hemihepatectomy of the liver and achieved effective resection. Conclusion: Foam sclerotherapy using polidocanol is clinically safe and effective for preoperative PVE.

• OSTI ID: 21608643
• Journal Information: Cardiovascular and Interventional Radiology, Vol. 34, Issue 6; Other Information: DOI: 10.1007/s00270-010-0079-5; Copyright (c) 2011 Springer Science+Business Media, LLC and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE); Country of input: International Atomic Energy Agency (IAEA); ISSN 0174-1551
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
BILIARY TRACT
CAT SCANNING
DISEASE INCIDENCE
FEMALES
FOAMS
HEPATOMAS
LIVER
MALES
MATERIALS
MORTALITY
PAIN
PATIENTS
SAFETY
VEINS
BLOOD VESSELS
BODY
CARCINOMAS
CARDIOVASCULAR SYSTEM
COLLOIDS
COMPUTERIZED TOMOGRAPHY
DIAGNOSTIC TECHNIQUES
DIGESTIVE SYSTEM
DISEASES
DISPERSIONS
GLANDS
NEOPLASMS
ORGANS
SYMPTOMS
TOMOGRAPHY